Questions across 2 calls

Parvati Rai

Equentis Wealth Advisory

Concord Biotech Limited

Concord Biotech Limited CC-Dec24.pdf · 2025-02-14

Yes. Thanks for taking my question. So, quick on the follow-up where we just hope that some of these orders have shifted to Q4. So, is there a possibility that it might move beyond Q4? And what I'm trying to ask is, will that grow? So, the shifting that has happened from Q3 to Q4, will that move from Q4 to Q1? Is there a possibility of that as well? Since we are banking so much on a strong quarter, because last quarter also, we did say that H2 would be much stronger. So, that's where I'm coming from.

Okay. A quick 1. So, the other income was quite high during this quarter. So, specifically, anything to call out there?

Krishna Institute of Medical Sciences Limited

Krishna Institute of Medical Sciences Limited CC-Jun24.pdf · 2024-08-08

A quick on the margin. So while we did say that it's sustainable for this year and the current quarter level margins of around 26.5% despite when you are -- I mean, the Nashik coming in, where the loss would be opposite. For next year, given Q4 and Q1 would see a couple of other hospitals coming online. Any colour if we can have there? What would be the sustainable EBITDA margin with these new hospitals coming in?

Yes. So any colour possibly with the other units. So I mean from a next year perspective as well should we see this level sustaining? Or will there be a slight change with the new hospitals coming in?